ClinicalTrialsFinder
RecruitingNCT07225738

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

Sponsor

City of Hope Medical Center

Enrollment

700 participants

Start Date

Jan 21, 2026

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma

Summary

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • \* Documented informed consent of the participant
  • Age: ≥ 18 years
  • ECOG ≤ 3
  • Ability to read and understand English
  • Patient must be newly diagnosed with a histologically confirmed multiple myeloma
  • Patients may have started first line therapies and received up to four cycles
  • HCP SURVEY: Documented informed consent of the participant
  • HCP SURVEY: Age: ≥ 18 years
  • HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse
  • HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients
  • HCP SURVEY: Able to read and understand English
  • HCP SURVEY: Affiliation with City of Hope

Exclusion Criteria7

  • \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy
  • Other active malignancy
  • Patients may not have undergone autologous hematopoietic stem cell transplantation
  • Unable to comply with the study assessments
  • HCP SURVEY: Reports directly to study PI (Dr. Richard Lee)
  • HCP SURVEY: Member of the study team or involved in survey design or analysis
  • HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses

Interventions

OTHERNon-Interventional Study

Non-interventional study

Locations(11)

CTCA at Western Regional Medical Center

Goodyear, Arizona, United States

City of Hope Medical Center

Duarte, California, United States

City of Hope Seacliff

Huntington Beach, California, United States

City of Hope at Irvine Lennar

Irvine, California, United States

City of Hope at Long Beach Elm

Long Beach, California, United States

City of Hope at Newport Beach Fashion Island

Newport Beach, California, United States

City of Hope South Pasadena

South Pasadena, California, United States

City of Hope Upland

Upland, California, United States

City of Hope West Covina

West Covina, California, United States

City of Hope Atlanta Cancer Center

Newnan, Georgia, United States

City of Hope at Chicago

Zion, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07225738

Related Trials

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT0725851133 locations

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

NCT068761421 location

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988873 locations

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT0709545225 locations

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT050924511 location